Novo Nordisk (NVO) Q2 2026 earnings review
Guidance Up, Quality Down
Novo Nordisk raised its 2026 outlook for the second time this year — adjusted sales growth now 0% to -6% at constant currency, up from -4% to -12% — and reported adjusted sales up 7% and adjusted operating profit up 11%. Shares still fell around 7%. The reason is what sits inside those numbers. Roughly DKK 2 billion of the quarter's sales were rebate credits for prior periods, and sales & distribution costs were cut 13% during the biggest product launch in the company's history. Strip out both and adjusted operating profit went backwards. The US, the source of the problem, grew 4% as reported but was around -1% underneath. Reported profit tells the other half of the story: operating profit fell 19% and EPS fell 20% after DKK 6.3 billion of pipeline write-offs. And the raised guidance still implies second-half adjusted sales decline of roughly 2% to 14%.
🐂 Bull Case
International Operations grew 10% and delivered 65% of all group growth, with Europe & Canada up 17% and contributing more than half the total on its own. International obesity sales rose 37% and international Wegovy injectable rose 46%. The UK pill launch lifted Novo's obesity market share there from around 30% to 45% within a month.
The DKK 8 billion savings programme is running ahead of plan. Headcount is 66,700, down almost 12,000 (15%) in twelve months. Sales & distribution fell to 19.1% of sales from 22.8%. That is why operating margin rose about a point year on year even though gross margin fell 4.5 points.
More than 5 million prescriptions in 30 weeks, around 265,000 a week, and roughly 90% of the US oral obesity market. Competing oral orforglipron is running at 22,000 weekly scripts. About 80% of pill patients had never taken a GLP-1.
🐻 Bear Case
US Wegovy injectable sales fell 22% at constant currency even though weekly injectable prescriptions rose to around 310,000 from roughly 280,000 a year ago. Total US obesity care sales grew 4% while the US branded obesity market grew 87% by volume. Novo is converting a booming market into almost no revenue growth.
Against +2% in the first half, full-year guidance implies second-half adjusted sales of roughly -2% to -14%. Free cash flow guidance of DKK 45-55 billion, after DKK 55.3 billion was already delivered in the first half, implies second-half free cash flow of about zero to negative DKK 10 billion.
The ziltivekimab ZEUS trial missed its primary endpoint outright (hazard ratio 0.99). Monlunabant was terminated, driving DKK 4.0 billion of a DKK 6.3 billion impairment. And CagriSema failed to prove non-inferiority against tirzepatide on blood sugar in the REIMAGINE 4 head-to-head, months before its US decision.
⚖️ Verdict: 🔴
Bearish on quality, not on the franchise. International execution and the cost reset are real and better than expected. But the growth that triggered the raise was bought with rebate credits, deferred spending and deferred tax payments, none of which repeat. The US business — two-thirds of the profit pool — is still going backwards on price, and the company has flagged a further 50% US list price cut for Wegovy from January 2027.
Key Themes
US Wegovy: More Scripts, Less Money
This is the single most important number in the release and it is not in the headline. US Wegovy injectable sales fell 22% at constant currency in Q2, an accelerating decline from roughly -12% in Q1. Volumes were not the problem: weekly US injectable prescriptions were around 310,000 versus roughly 280,000 a year earlier. Price and channel did the damage. Self-pay is now about 35% of US injectable Wegovy, against 10-15% a year ago, and self-pay sits at a materially lower price point. Total US Wegovy prescriptions (injectable plus pill) roughly doubled year on year while total US obesity care revenue rose just 4% — against a US branded obesity market growing 87% by volume. Management framed the quarter as market leadership by new patient starts. That is true and beside the point: Novo is capturing the volume and giving away the value.
DKK 2 Billion of the Quarter Was a Rebate Credit
The release describes 'favourable US rebate adjustments' without sizing them. On the call, US head Jamey Millar put the figure at DKK 2 billion, about three-quarters of it Ozempic gross-to-net and the rest insulin. These are corrections to prior-period accruals, not demand. Removing them changes the picture materially: group adjusted sales growth falls from 7% to about 4%; US Operations goes from +4% to roughly -1%; US GLP-1 diabetes goes from +3% to about -4%; and US insulin's eye-catching +15% becomes about -4%, which is what you would expect given the report itself notes market share losses in a declining insulin market. The company has now taken favourable gross-to-net adjustments in three of the last four reported periods.
Costs Did the Heavy Lifting — and Management Says That Reverses
Sales & distribution costs fell 13% at constant currency and DKK 2.5 billion in absolute terms, in the same quarter Novo was launching the Wegovy pill, Wegovy HD and defending share against tirzepatide. Adjusted R&D fell 2%, which the CFO attributed to 'phasing across quarters'. Do the arithmetic: had sales & distribution simply been held flat year on year, adjusted operating profit would have been about DKK 30.9 billion against DKK 30.8 billion a year ago — no growth at all. Take out the DKK 2 billion rebate credit as well and it declines. Guidance states plainly that R&D spend and promotional activity increase in the second half. The 11% operating profit growth is a timing artefact, not a run rate.
International Operations Now Carry the Company
International Operations delivered 65% of group growth in the quarter, with Europe & Canada alone contributing 53%. Europe & Canada grew 17%, China 13%, Emerging Markets 5%, while the US managed 4% only with rebate help and APAC fell 6%. Within international, obesity sales rose 37% (decelerating from 44% in Q1 but off a much larger base) and Wegovy injectable rose 46%, with Europe & Canada up 63%. Ozempic international sales rose 10%, helped by the 2.0 mg rollout now live in around ten countries with more than 20 launches planned this year. Wegovy is now available in around 60 countries. The offset: the first generic semaglutide entries have arrived in early loss-of-exclusivity markets, and management expects that impact to be back-end loaded into the second half.
The Wegovy Pill Is the Fastest GLP-1 Launch Ever Run
Six months in, the pill has passed 5 million total US prescriptions, with around 2.9 million written in Q2 alone, and has taken roughly 90% of the US oral obesity market despite a competitor launching in early April. At week 30 the pill was running at about 265,000 weekly prescriptions versus 120,000 for tirzepatide and 22,000 for orforglipron. Around 80% of patients are new to GLP-1s, and management says cannibalisation of injectable Wegovy has been limited. Q2 US pill sales were DKK 3,141 million. It is available in more than 70,000 pharmacies and through nine telehealth partners, at USD 149-299 per month depending on dose. The company also flags that external data providers still under-capture pill scripts, so reported volumes may understate the franchise.
Pill Momentum Is Slowing, and It Sits in the Cheap Doses
Weekly prescriptions went from roughly 50,000 in late January to 207,000 by mid-April to 265,000 by mid-July. That is still growth, but the weekly rate of addition fell from around 13,000 per week in the first stretch to about 4,500 per week in the second. Only 30% of prescriptions are for the 9 mg and 25 mg doses, which are the ones priced at the top of the USD 149-299 range — meaning 70% of the book sits in the cheapest tiers. UBS put it directly on the call: momentum appears to be stalling, and asked whether Novo should cut higher-dose prices. Management declined, preferring a 'targeted surgical' subscription approach. That subscription programme has 30,000 patients enrolled in total, of which only 2,000 are pill patients. Management's framing — 'the latest 1 million prescriptions were added in just four weeks' — is a refill base effect, not accelerating demand.
Cash Flow Looks Excellent and Mostly Isn't
First-half free cash flow of DKK 55.3 billion against DKK 38.4 billion looks like a step change, and drove a DKK 9 billion increase in the full-year guide. Operating cash flow improved by DKK 12.8 billion. Tax payables rose by DKK 12.0 billion over the same period, to DKK 20.5 billion from DKK 8.4 billion, while cash tax paid fell to DKK 7.3 billion against a DKK 19.5 billion tax charge. Essentially the whole improvement is tax not yet paid. Underneath, working capital was a DKK 19.9 billion drag versus DKK 7.5 billion last year: trade receivables jumped 25.5% to DKK 88,949 million against reported first-half sales up 13%, and trade payables fell 26%. Novo is collecting more slowly and paying suppliers faster while deferring tax. Plausible explanations for the receivables build are the telehealth and self-pay channel ramp and pipeline fill for three launches, but the size of the gap warrants monitoring.
Paying to Unwind the Capacity Build
Adjusted gross margin fell to 78.2% from 82.7%, and the year-on-year decline is accelerating: -2.9 points in Q1, -4.5 points in Q2. Inside that sits about DKK 3 billion of one-time costs for 'right-sizing of manufacturing capacity agreements' — roughly 3.8 points of the 4.5 point fall. Excluding it, underlying gross margin held up much better than the headline suggests, which is the good news. The bad news is what the charge represents: after five years and roughly DKK 210 billion of cumulative capital expenditure, Novo is now paying to exit third-party capacity. Meanwhile the CFO described utilisation at the new owned API facilities as 'very low utilisation', with only the first product validated in the first line of the first plant. Low utilisation of newly commissioned plants is a fixed-cost absorption drag that sits ahead of the company, not behind it.
Three Pipeline Setbacks, One Quarter
The ZEUS trial of ziltivekimab in cardiovascular disease with chronic kidney disease and inflammation missed its primary endpoint with a hazard ratio of 0.99, despite hitting its biomarkers, and showed more serious infections. Management had flagged roughly 50% probability of success, so it is not a shock, but two further ziltivekimab outcome trials (HERMES and ARTEMIS) now run to first half 2027 on a hypothesis that just failed its cleanest test, and the report warns of a further non-cash impairment in Q3 2026. Monlunabant was terminated outright, driving DKK 4.0 billion of the DKK 6.3 billion Q2 impairment. Most consequentially, the REIMAGINE 4 head-to-head showed CagriSema non-inferior to tirzepatide 15 mg on weight (15.2% vs 15.8%) but failing non-inferiority on HbA1c (1.9 vs 2.2 percentage points) — in type 2 diabetes, where blood sugar is the endpoint that sells the drug. The US obesity decision is due at the end of 2026. Note the press release's pipeline section listed both EMA approvals and the ZEUS failure but omitted the REIMAGINE 4 result entirely.
The US Policy Bill Comes Due in 2027 — and CVS Opens the Door in October
Two forward items in the report were not raised once in prepared remarks or Q&A. First, effective 1 October 2026, CVS Caremark will add other weight-loss medications to its largest commercial template formularies — dismantling the exclusive position Novo won in July 2025 at a pharmacy benefit manager with roughly 26% of the US market. Second, from 1 January 2027 Novo will cut US list prices to USD 675 for Wegovy injection and tablets and for Ozempic — reductions of approximately 50% and 35% respectively — and the company states this will affect 2027 cash flow. On the positive side of the same ledger, the Medicare Part D 'Bridge' pilot went live on 1 July 2026 covering a majority of beneficiaries at a USD 50 copay, and management reports encouraging early volumes while noting it is too early to judge durability. Set against Medicaid coverage reductions in several states and the Most Favoured Nations agreement, the US policy mix is a volume-for-price trade with the price side arriving first.
The Pill's Real Moat Is Its Label, Not Its Weight Loss
The most durable competitive point Novo made this quarter is a drug-interaction table. Oral semaglutide has no labelled interaction with strong or moderate CYP3A4 inhibitors and inducers, with simvastatin, or with oral contraceptives, and no significant differences in severe hepatic impairment. Orforglipron carries restrictions or avoidance language on every one of those, including a requirement to use non-oral or barrier contraception. For a mass-market chronic drug taken by tens of millions of people already on statins and contraceptives, that is a bigger practical differentiator than the 16.6% versus 17% weight-loss debate. The EU approval also carries SELECT cardiovascular outcomes data in the label. Alongside this, Novo added the FlexTouch pen and manual prefilled syringe device approvals and a first-of-its-kind 3, 6 and 12-month subscription plan for self-pay patients.
Emerging Markets and APAC Are Deteriorating
Two regions are moving the wrong way and are getting little airtime. APAC adjusted sales fell 6% in the quarter and APAC obesity care fell 9%, the only negative obesity region in the group. Emerging Markets GLP-1 diabetes sales fell 22% in the quarter and 31% in the first half, with injectable GLP-1 down 35%. Region China obesity grew 104% but off a tiny DKK 335 million base and against list price cuts taken in late 2025, and China rare disease sales fell 82%. Emerging Markets and APAC together are about 17% of group sales and are currently subtracting from growth.
Other KPIs
Down from 82.7% a year ago and from 80.6% in Q1 2026 — the fifth consecutive quarter of year-on-year decline, and the decline is widening. About DKK 3 billion of one-time manufacturing right-sizing cost accounts for roughly 3.8 points of the 4.5 point drop; the rest is lower realised prices and currency, partly offset by productivity and GLP-1 mix. The contrast with operating margin is the story of the quarter: adjusted operating margin actually rose to 42.5% from about 41.5%, because sales & distribution absorbed the gross margin damage. That lever is now largely pulled.
The gap is 30% and it is worth understanding before using either number. Reported diluted EPS fell 20% and reported operating profit fell 19%, hit by the DKK 6.3 billion pipeline impairment this year and the absence of last year's DKK 2.6 billion 340B benefit. Adjusted diluted EPS rose 5%. Neither is clean: the reported number is depressed by write-offs that reflect genuine value destruction in the pipeline, while the adjusted number is inflated by rebate credits and deferred spending. Reported net profit was DKK 20,989 million, down 21%.
Reversing. A year ago this segment made DKK 518 million; it now shows a -26.4% operating margin on sales that were flat at DKK 4,907 million. The swing is driven by an allocation of the quarter's impairment charges. Underlying sales were reasonable — rare endocrine disorders grew 24% on Norditropin and Sogroya, while rare blood disorders fell 4% on NovoSeven weakness. Etavopivat in sickle cell disease is filing in the US and EU in Q4 2026 and denecimig has a US and EU decision due in Q3, so the segment has near-term catalysts even as its reported profitability is currently meaningless.
Net debt improved to DKK 86.5 billion from DKK 95.4 billion at the end of 2025, helped by the cash timing described above. Equity is 37.2% of total assets, up from 35.7%. Novo paid DKK 35.3 billion in dividends and repurchased DKK 5.9 billion of shares in the first half, with DKK 7.5 billion of the DKK 15 billion buyback completed by 3 August. An interim dividend of DKK 3.75 per share will be paid in August. Note the ratio: buybacks remain roughly one-sixth the size of the dividend, so the equity-return cushion against further price erosion is thin. Headcount fell to 66,700, down almost 12,000 or 15% year on year.
Guidance
Decelerating sharply from here. The midpoint moves from -8% to -3%, a five point raise, but most of that is banking the Q2 beat rather than upgrading the rest of the year. Against +2% delivered in the first half, the range implies second-half growth of roughly -2% at the top and -14% at the bottom, midpoint around -8%. The CFO's own bridge: take the current run rate, subtract semaglutide loss of exclusivity in Canada and Brazil which starts biting in H2, and subtract the DKK 5 billion of favourable gross-to-net adjustments that sat in the Q3 and Q4 2025 base and do not repeat — worth roughly 3 points on its own. Achievability: given Q2's underlying rate was about +4% before rebate credits, the upper half of the range looks reachable and the -6% floor looks conservative. In Danish kroner, growth is expected around 1 point lower than at CER.
Decelerating from +11% in Q2 and +2% in the first half to roughly -8% implied at the midpoint for the second half. Two things pull in opposite directions. Against it: management explicitly guides higher R&D and promotional spend in H2, and gross margin pressure continues. For it: on the company's own definition, adjusted operating profit excludes major legal matters, major impairments and 340B reversals — but not major restructuring costs. The Q3 2025 base therefore carries roughly DKK 8-9 billion of transformation charges, making the Q3 comparison unusually easy. That asymmetry is not discussed anywhere in the materials and materially raises the odds of the top of the range. In Danish kroner, growth is expected around 2 points lower than at CER.
Raised by DKK 9 billion, and the most revealing number in the outlook. First-half free cash flow was already DKK 55.3 billion — at or above the entire full-year range. That implies second-half free cash flow of roughly zero at the very top end and about negative DKK 10 billion at the bottom, with a midpoint near negative DKK 5 billion. Management attributes the first-half strength to phasing of operating expenses and the timing of US rebate and tax payments, which is precisely why it reverses. This is the clearest confirmation available that the first half borrowed cash from the second.
Stable versus prior guidance and down from DKK 60 billion in 2025. First-half capex was DKK 24.0 billion, down 15%, implying around DKK 31 billion in the second half — a step up sequentially. Management repeats that capex declines in coming years. Taken with the DKK 3 billion charge to right-size third-party capacity agreements and the CFO's comment that new API plants are running at very low utilisation, the capital cycle has turned but the depreciation and absorption consequences have not yet fully hit the P&L.
The one item guided worse. The loss expectation nearly doubles, reflecting interest expense on net debt partly offset by US dollar hedging gains. Q2 financial items were a net loss of DKK 186 million against a net gain of DKK 356 million a year ago. Effective tax rate is unchanged at 21-23%.
Approximately -50% for Wegovy injection 2.4 mg and 7.2 mg and tablets, and approximately -35% for Ozempic, across all doses. The company states this will affect 2027 cash flow. This sits entirely outside the 2026 guidance and is the largest single known variable for next year. Management declined to guide 2027 on the call beyond 'start with the current run rate', while noting that the loss-of-exclusivity drag annualises into 2027 whereas the favourable 2025 comparator effects do not.
Key Questions
Why does the cash flow guidance imply a negative second half?
First-half free cash flow of DKK 55.3 billion already meets the top of the full-year DKK 45-55 billion range. How much of the second-half reversal is US rebate settlement, how much is the DKK 20.5 billion tax payable unwinding, and what is the normalised quarterly free cash flow run rate once both have cleared?
What happens on 1 October when CVS opens its formulary?
The report discloses that CVS Caremark will add other weight-loss medications to its largest commercial template formularies effective 1 October 2026, reversing the exclusive position secured in July 2025. This was not mentioned in prepared remarks or in any answer. What volume and price impact is assumed in the 2026 guidance, and what share of Wegovy's insured volume is exposed?
What is the gross profit step-down from the 2027 list price cut?
Wegovy list prices fall roughly 50% and Ozempic roughly 35% from 1 January 2027. Given the shift to self-pay, realised prices are already well below list. What is the net realised price impact after rebate offsets, and does the 'current run rate' starting point for 2027 guidance embed it?
How much more capacity right-sizing is coming?
The DKK 3 billion charge to exit manufacturing capacity agreements arrives while newly built API facilities run at what the CFO called very low utilisation. What is the remaining exit cost across third-party agreements, and what is the fixed-cost absorption drag on gross margin as the new plants ramp?
Where does US realised price per prescription bottom?
US injectable Wegovy revenue fell 22% on roughly 11% more prescriptions — an implied price and mix decline of around 30 points, with self-pay now 35% of volume versus 10-15% a year ago. At what self-pay mix does this stabilise, and what is the realised revenue per prescription today versus a year ago?